# USANA Schedules Second Quarter 2026 Earnings Release and Conference Call
Canonical URL: https://biopharmsignal.com/news/USNA/usana-schedules-second-quarter-2026-earnings-release-and-conference-call-d0dc753b
Ticker: USNA
Company: Usana Health Sciences, Inc.
Source: Usana Health Sciences, Inc.
Published: 2026-07-14 20:15 EST
Original Source URL: /news-events/press-releases/detail/836/usana-schedules-second-quarter-2026-earnings-release-and
## Article Body
SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2026 results will be released after the close of market on Tuesday, August 4, 2026. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website ( http://ir.usana.com ) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, August 5, 2026 at 11:00 a.m. Eastern Time.

The call will be broadcast over the Internet and can be accessed at http://ir.usana.com .

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers across 25 global markets. More information on USANA can be found at www.usana.com . USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com . More information on Rise Wellness can be found on www.risebar.com and www.proteinpop.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260714328067/en/

Investor contact:

Investor Relations

(801) 954-7201

investor.relations@usanainc.com Andrew Masuda

Source: USANA Health Sciences, Inc.
## Recent Company News
- 2026-07-20 11:06 EST — [USANA Health Sciences Renews Four-Year Partnership with Nordiq Canada, Deepening Commitment to Clean Sport and Elite Athlete Nutrition](https://biopharmsignal.com/news/USNA/usana-health-sciences-renews-four-year-partnership-with-nordiq-canada-deepening--7aaacadb) — Source: Usana Health Sciences, Inc.
- 2026-07-14 20:15 EST — [USANA Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/USNA/usana-schedules-second-quarter-2026-earnings-release-and-conference-call-d0dc753b) — Source: Usana Health Sciences, Inc.
- 2026-07-01 11:02 EST — [Kevin Guest: World Cup Determination Shows the Power of Grit, Preparation, Persistence](https://biopharmsignal.com/news/USNA/kevin-guest-world-cup-determination-shows-the-power-of-grit-preparation-persiste-ce0b681d) — Source: Usana Health Sciences, Inc.
- 2026-06-25 13:46 EST — [USANA Celebrates 10 Years of Making the World a Better Place During World Service Week](https://biopharmsignal.com/news/USNA/usana-celebrates-10-years-of-making-the-world-a-better-place-during-world-service-week) — Source: Usana Health Sciences, Inc.
- 2026-06-25 13:46 EST — [USANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products](https://biopharmsignal.com/news/USNA/usana-s-celavive-contouring-face-and-neck-creme-named-among-canada-s-top-skincare-products) — Source: Usana Health Sciences, Inc.
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)